 Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
| Descriptor ID |
D048493
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
| Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- BRAF Kinases
- B-raf Kinases
- B raf Kinases
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 3 | 0 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 4 | 1 | 5 | | 2013 | 2 | 5 | 7 | | 2014 | 7 | 5 | 12 | | 2015 | 6 | 4 | 10 | | 2016 | 3 | 4 | 7 | | 2017 | 8 | 2 | 10 | | 2018 | 5 | 7 | 12 | | 2019 | 4 | 4 | 8 | | 2020 | 4 | 5 | 9 | | 2021 | 4 | 2 | 6 | | 2022 | 2 | 6 | 8 | | 2023 | 3 | 4 | 7 | | 2024 | 5 | 2 | 7 | | 2025 | 4 | 1 | 5 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Vieito M, Cabanas EG, Mehmi I, Gaudy-Marqueste C, O'Neil BH, Medina TM, Body AL, Arance A, Kummar S, Najjar YG, Bedard PL, Rankin A, Chu C, McKenna C, Hume S, Kopp LM, Lee J. Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy. JCO Precis Oncol. 2026 Oct; 10(10):e2501187.
-
Schreck KC, de la Fuente MI, Lim Fat MJ, Maas SLN, Mulcahy Levy JM, Lombardi G, Perrault S, Petritsch CK, Aldape K, Chang SM, Duerinck J, Holdhoff M, Kazda T, Le Rhun E, Minniti G, Mishra MV, Mueller S, Padovan M, Preusser M, Smits M, Weller M, Wen PY, van den Bent M, Geurts M. BRAF-altered glioma in adults and children: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on clinical management and future directions. Neuro Oncol. 2026 Oct 01; 28(10):2313-2335.
-
Corey Z, Wiredja D, Willard N, Wisell J, Raghavan SS. Spitz Nevi With Novel BRAF Fusions: A Report of Two Cases With Striking Morphologic Features. Am J Dermatopathol. 2026 May 01; 48(5):397-401.
-
Nangia V, Ashraf H, Marikar N, Passanisi VJ, Ill CR, Spencer SL. MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells. Sci Signal. 2025 Sep 02; 18(902):eadw3231.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 09 16; 135(18).
-
Roy SF, Agim NG, Mir A, Couts KL, Vandergriff T, Robinson WA, Bastian BC, Frieden IJ, Yeh I. Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. Br J Dermatol. 2025 07 17; 193(2):232-239.
-
Zahedi S, Riemondy K, Liu T, Griesinger AM, Donson AM, Apfelbaum AA, Fu R, Grandvallet Contreras J, Crespo M, DeSisto J, Groat MM, Bratbak E, Green A, Hankinson TC, Handler M, Vibhakar R, Willard N, Foreman NK, Phang T, Mulcahy Levy J. Multi-pronged analysis of pediatric low-grade glioma and ganglioglioma reveals a unique tumor microenvironment associated with BRAF alterations. Brain Pathol. 2025 11; 35(6):e70023.
-
Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Monje M, Xiu J, Beck A, Weber KJ, Harter PN, Lim M, Mahaney KB, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK. BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma. Cell Rep Med. 2025 Jun 17; 6(6):102183.
-
Jasim S, Golding A, Bimston D, Alshalalfa M, Chen Y, Jiang R, Hao Y, Huang J, Klopper JP, Kloos RT, Brown TC. Cytologic and Molecular Assessment of Isthmus Thyroid Nodules and Carcinomas. Thyroid. 2025 03; 35(3):255-264.
-
Webster J, Ghith J, Penner O, Lieu CH, Schijvenaars BJA. Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing. JCO Precis Oncol. 2024 10; 8:e2300685.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|